0001140361-21-006738.txt : 20210301 0001140361-21-006738.hdr.sgml : 20210301 20210301191245 ACCESSION NUMBER: 0001140361-21-006738 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210225 FILED AS OF DATE: 20210301 DATE AS OF CHANGE: 20210301 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Attar Eyal C. CENTRAL INDEX KEY: 0001789076 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39069 FILM NUMBER: 21700457 MAIL ADDRESS: STREET 1: 535 BOYLSTON STREET CITY: BOSTON STATE: MA ZIP: 02116 FORMER NAME: FORMER CONFORMED NAME: Attar Eyal DATE OF NAME CHANGE: 20190923 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Aprea Therapeutics, Inc. CENTRAL INDEX KEY: 0001781983 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 535 BOYLSTON STREET CITY: BOSTON STATE: MA ZIP: 02116 BUSINESS PHONE: 6095104718 MAIL ADDRESS: STREET 1: 535 BOYLSTON STREET CITY: BOSTON STATE: MA ZIP: 02116 4 1 form4.xml FORM 4 X0306 4 2021-02-25 0001781983 Aprea Therapeutics, Inc. APRE 0001789076 Attar Eyal C. 535 BOYLSTON STREET BOSTON MA 02116 true SVP, Chief Medical Officer Common Stock 2021-02-25 4 A 0 33000 0 A 33000 D Common Stock 2021-02-25 4 A 0 75000 0 A 108000 D Common Stock 200 I By adult child Common Stock 200 I By child Stock Option (right to Buy) 6 2021-02-25 4 A 0 143000 0 A 2031-02-25 Common Stock 143000 143000 D These shares represent restricted stock units which were granted on February 25, 2021, and which will vest and be settled in common stock as follows: (i) 11,000 shares on February 25, 2022, (ii) 11,000 shares on February 25, 2023 and (iii) 11,000 shares on February 25, 2024, subject to the reporting person's continued employment through and including the applicable vesting dates and subject to acceleration under certain conditions. These shares represent restricted stock units which were granted on February 25, 2021, and which will vest and be settled in common stock as follows: (i) 25,000 shares on August 25, 2021, (ii) 25,000 shares on February 25, 2022 and (iii) 25,000 shares on August 25, 2022, subject to the reporting person's continued employment through and including the applicable vesting dates and subject to acceleration under certain conditions. Twenty-five percent of these options vest on February 25, 2022, with the remaining options vesting ratably over the following 36 months, subject to the reporting person's continued employment through and including the applicable vesting date and subject to acceleration under certain conditions. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, or for any other purpose. /s/ Scott M. Coiante, attorney-in-fact 2021-03-01